300313.SZ
天山生物
SZSE · Consumer Defensive · A 农林牧渔 · CN
CNY 15.36
+20.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 294.2M | 200.3M | 137.6M | 137.5M | 76.4M |
| Cost of Revenue | 270.5M | 185.5M | 144.8M | 114.1M | 65.5M |
| Gross Profit | 23.7M | 14.8M | (7.2M) | 23.4M | 10.8M |
| Operating Expenses | |||||
| R&D Expense | 949.2K | 1.0M | 1.2M | 1.6M | 565.3K |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 23.5M | 23.5M | 22.3M | 22.0M | 15.6M |
| Selling & Marketing Expense | 3.0M | 2.7M | 4.8M | 4.5M | 3.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 36.2M | 37.0M | 39.2M | 38.9M | 33.2M |
| Cost and Expenses | 306.7M | 222.5M | 184.0M | 153.0M | 98.8M |
| Operating Income (EBIT) | (12.2M) | (22.0M) | (61.3M) | (18.7M) | (28.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (12.2M) | (22.0M) | (63.4M) | (19.3M) | (30.5M) |
| Income Tax Expense | 4.4M | 4.2M | 3.7M | 2.8M | 1.6M |
| Bottom Line | |||||
| Net Income | (18.1M) | (27.2M) | (65.9M) | (22.0M) | (31.8M) |
| Earnings from Cont. Ops | (16.6M) | (26.2M) | (67.1M) | (22.1M) | (32.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (18.1M) | (27.2M) | (65.9M) | (22.0M) | (31.8M) |
| Per Share | |||||
| Basic EPS | (CN¥0.05) | (CN¥0.09) | (CN¥0.21) | (CN¥0.07) | (CN¥0.10) |
| Diluted EPS | (CN¥0.05) | (CN¥0.09) | (CN¥0.21) | (CN¥0.07) | (CN¥0.10) |
| Revenue Per Share | CN¥1.23 | CN¥0.65 | CN¥0.44 | CN¥0.44 | CN¥0.24 |
| Shares | |||||
| Basic Shares Outstanding | 239.2M | 307.2M | 313.0M | 314.3M | 318.3M |
| Diluted Shares Outstanding | 239.2M | 307.2M | 313.0M | 314.3M | 318.3M |
| Profitability Metrics | |||||
| EBITDA | — | (8.6M) | (47.6M) | (4.6M) | (14.0M) |
| D&A | — | 13.4M | 13.7M | 14.1M | 14.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026